Celebrex CV Risk v. Naproxen, Ibuprofen: US FDA Does Not Recommend Differential Labeling
Advisory committee to evaluate whether PRECISION trial shows celecoxib cardiovascular safety is comparable to naproxen and ibuprofen and if naproxen and ibuprofen use should be contraindicated with aspirin.
You may also be interested in...
Despite concerns about difference in dosages and study discontinuation rates, US FDA advisory committee concludes that Pfizer's study demonstrated similar CV risk among the three NSAIDs.
Companies with pipeline pain products may see a smoother path through FDA, but Celebrex already has generic competition in the US, limiting the benefits even if it could get the black box removed from labeling and Pfizer also recently settled a lawsuit for $468 million related to the drug's safety.
Pfizer's COX-2 inhibitor Celebrex can remain on the market with new labeling warnings, including a "black box" about the increased risk of cardiovascular events, an FDA advisory committee recommended Feb. 18